<DOC>
	<DOCNO>NCT01152567</DOCNO>
	<brief_summary>The plan Study retrospective study effect ACE 's vs. candesartan cardiovascular event health economic effect `` real life '' set Sweden .</brief_summary>
	<brief_title>Effects Angiotensin Converting Enzyme ( ACE ) Inhibitors Versus Candesartan Reducing Cardiovascular Events Primary Treatment Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>patient find electronic patient journal participate centre , prescribe either ACEis ( ATCC09AB ) ARBs ( C09CD ) hypertension 1 January 1999 31 December 2007 . The first date prescription start observation time call index prescription . No history cardiovascular disease . Ongoing malignancy</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>ACE</keyword>
	<keyword>ARB</keyword>
	<keyword>real life data</keyword>
	<keyword>CVD</keyword>
	<keyword>cost effectiveness</keyword>
</DOC>